Deutsche Bank upgraded Argenx (EBR:ARGX) to Buy from Hold and raised its target price to 5
Summary
Deutsche Bank has upgraded Argenx to a Buy rating and increased its price target to
Detailed analysis
Analyst Emmanuel Papadakis described Argenx's fourth-quarter trading update as "somewhat underwhelming." He characterised the reported numbers themselves as "unremarkable," while noting the overall release was mixed on several fronts - specifically R&D newsflow, the immediate outlook for the first quarter and the absence of a refreshed guidance framework, which he described as a "surprising step back on guidance framework (there wasn't any)."
Following that release, shares of the biopharmaceutical company declined by roughly 10% from the levels seen after the results were published in late February. Papadakis also referenced recent management changes at the firm, including a CEO transition that had attracted investor attention, writing that "a little weakness in light of that was perhaps understandable."
Despite noting these mixed elements, the analyst pointed to a number of stabilising and constructive factors underpinning his decision to upgrade the stock. He cited continued commercial momentum for Argenx's principal therapy, Vyvgart, and a strengthening of the company's balance sheet position.
Papadakis highlighted that Argenx holds around $4 billion in cash, which he estimated to be approximately 10% of the company's market capitalisation. He also noted that Argenx is now consistently profitable.
Valuation considerations were central to the move. Since Deutsche Bank's previous downgrade last autumn, the bank's expectations for Vyvgart's long-term sales potential have risen, with peak sales now forecast to exceed $10 billion. At that level of peak revenue, Papadakis calculated that the shares imply a peak-sales multiple of less than four times, which he argued represents "a discount to any net present value (NPV) that ascribes terminal value (which it likely should given the Vyvgart-monthly lifecycle programme) even if it ignores other pipeline opportunities."
"With Vyvgart commercial momentum looking intact overall plus c10% of the market cap in cash (c$4bn) and ARGX now consistently profitable, valuation is no longer as demanding as it was previously either," Papadakis wrote.
He further noted that Argenx's growth outlook supports the valuation, observing that the shares trade on a fiscal 2026 price-to-earnings multiple of about 26 times for a business expected to grow its topline by roughly 50% in the current year.
Looking ahead, Papadakis identified the next material catalysts as a series of clinical readouts slated for the second half of the year. These include Vyvgart efficacy results in myositis from the ALKIVIA study and data for empasiprubart in multifocal motor neuropathy from the EMPASSION trial. He said he remains "relatively constructive" on those forthcoming data points and intends to reassess the investment case in greater detail as the readouts approach.
Key points
- Deutsche Bank upgraded Argenx to Buy from Hold and raised its price target to
- Argenx holds about $4 billion in cash - roughly 10% of market cap - and has become consistently profitable.
- Analyst expectations for Vyvgart peak sales have increased to more than $10 billion, implying a peak-sales multiple below four times and a fiscal 2026 P/E of around 26x on anticipated strong revenue growth.
Risks and uncertainties
- The company's recent fourth-quarter update was assessed as "somewhat underwhelming," with mixed signals on R&D newsflow and near-term guidance - factors that may affect investor sentiment in the short term.
- Management changes including a CEO transition could contribute to volatility in the shares as investors digest leadership turnover.
- Clinical readouts in the second half of the year - including ALKIVIA and EMPASSION study results - represent event-driven risks; outcomes could materially influence the investment case depending on their content.